Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 19, 2021

Primary Completion Date

June 9, 2023

Study Completion Date

June 9, 2023

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

REGEND001

Transplantation of REGEND001 for dose escalation.

Trial Locations (3)

Unknown

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

Peking Union Medical College Hospital

OTHER

collaborator

Ruijin Hospital

OTHER

collaborator

The First Affiliated Hospital of Guangzhou Medical University

OTHER

collaborator

Regend Therapeutics XLotus (Jiangxi) Co, Ltd.

UNKNOWN

lead

Regend Therapeutics

INDUSTRY

NCT05657184 - Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001 | Biotech Hunter | Biotech Hunter